

INVIVO THERAPEUTICS HOLDINGS CORP.  
Form 8-K  
December 12, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 or 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**December 8, 2013**

**Date of Report (Date of earliest event reported)**

**INVIVO THERAPEUTICS HOLDINGS CORP.**  
**(Exact Name of Registrant as Specified in Charter)**

**NEVADA**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**000-52089**  
**(Commission**  
**File Number)**

**36-4528166**  
**(IRS Employer**  
**Identification No.)**

**One Kendall Square, Suite B14402**

**Cambridge, Massachusetts 02139**

**(Address of Principal Executive Offices) (Zip Code)**

**(617) 863-5500**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 8, 2013, Gregory D. Perry, Interim Chief Financial Officer of InVivo Therapeutics Holdings Corp. (the Company ), whose term was set to expire on December 16, 2013, notified the Company that he would be pursuing another opportunity.

On December 11, 2013, the Company and Mr. Perry entered into an amendment to Mr. Perry's employment agreement to extend his term through December 30, 2013. During this extension, Mr. Perry will commit four days per week to the Company.

The Board of Directors is continuing its search for a permanent Chief Financial Officer.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVO THERAPEUTICS HOLDINGS CORP.

Date: December 12, 2013

By: /s/ Michael J. Astrue  
Michael J. Astrue  
Interim Chief Executive Officer